Elcelyx Continues Work On Weight Loss Supplement With $7 Mil. Financing
The Series B funding enables the San Diego biotech to advance a weight loss supplement to the cusp of commercialization. Elcelyx, also moving a delayed-release formulation of diabetes drug metformin into mid-stage trials, so far has received some $20 million in venture capital.
Biotechnology firm Elcelyx Therapeutics Inc.received a $7 million extension of its Series B financing in part to continue developing its Lovidia nutritional supplement for weight loss.
